Identification and functional implications of sodium/myo-inositol cotransporter 1 in pancreatic β-cells and type 2 Diabetes

11Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Myo-inositol (MI), the precursor of the second messenger phosphoinositide (PI), mediates multiple cellular events. Rat islets exhibit active transport of MI, although the mechanism involved remains elusive. Here, we report, for the first time, the expression of sodium/myo-inositol cotransporter 1 (SMIT1) in rat islets and, specifically, β-cells. Genetic or pharmacological inhibition of SMIT1 impaired glucose-stimulated insulin secretion by INS-1E cells, probably via downregulation of PI signaling. In addition, SMIT1 expression in INS-1E cells and isolated islets was augmented by acute high-glucose exposure and reduced in chronic hyperglycemia conditions. In corroboration, chronic MI treatment improved the disease phenotypes of diabetic rats and islets. On the basis of our results, we postulate that the MI transporter SMIT1 is required to maintain a stable PI pool in β-cells in order that PI remains available despite its rapid turnover.

Cite

CITATION STYLE

APA

Li, S. Y. T., Cheng, S. T. W., Zhang, D., & Leung, A. P. S. (2017). Identification and functional implications of sodium/myo-inositol cotransporter 1 in pancreatic β-cells and type 2 Diabetes. Diabetes, 66(5), 1258–1271. https://doi.org/10.2337/db16-0880

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free